Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

被引：39
作者：
van der Kooij, M. K. [1 ]
Joosse, A. [1 ]
Speetjens, F. M. [1 ]
Hospers, G. A. P. [2 ]
Bisschop, C. [2 ]
de Groot, J. W. B. [3 ]
Koornstra, R. [4 ]
Blank, C. U. [5 ]
Kapiteijn, E. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Dept Clin Oncol, POB 9600, NL-2300 RC Leiden, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, Groningen, Netherlands
[3] Isala, Dept Med Oncol, Zwolle, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Med Oncol, Nijmegen, Netherlands
[5] Netherlands Canc Inst NKI AVL, Dept Med Oncol, Amsterdam, Netherlands
来源：
ACTA ONCOLOGICA | 2017年 / 56卷 / 01期
关键词：
IPILIMUMAB; TRIAL;
D O I：
10.1080/0284186X.2016.1260773
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：101 / 103
页数：3
相关论文
共 50 条
  • [1] Anti-PD1 role in treatment of cutaneous melanoma
    Mateus, Christine
    Libenciuc, Cristina
    Robert, Caroline
    BULLETIN DU CANCER, 2016, 103 (06) : S4 - S11
  • [2] Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?
    Bender, Carolin
    Enk, Alexander
    Gutzmer, Ralf
    Hassel, Jessica C.
    CANCER MEDICINE, 2017, 6 (07): : 1581 - 1586
  • [3] Predicting the response to anti-PD1 therapy in metastatic melanoma
    Heinzerling, Lucie
    Kirchberger, Michael Constantin
    Walter, Lisa
    Schuler, Gerold
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S576 - S579
  • [4] Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma
    Lee, J. H.
    Long, G. V.
    Boyd, S.
    Lo, S.
    Menzies, A. M.
    Tembe, V.
    Guminski, A.
    Jakrot, V.
    Scolyer, R. A.
    Mann, G. J.
    Kefford, R. F.
    Carlino, M. S.
    Rizos, H.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1130 - 1136
  • [5] Dermatological oncology: advanced melanoma, side effects of anti-PD1, place of monotherapy in the first line, treatment of metastatic melanoma
    Kluger, N.
    Lebbe, C.
    Grange, F.
    Mortier, L.
    Robert, C.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2017, 144 : S11 - S14
  • [6] Hepatic Radiotherapy in Addition to Anti-PD-1 for the Treatment of Metastatic Uveal Melanoma Patients
    Rossi, Ernesto
    Cellini, Francesco
    Pagliara, Monica Maria
    Sammarco, Maria Grazia
    Pedone, Romina Rose
    Lancellotta, Valentina
    Tagliaferri, Luca
    Quirino, Michela
    Gambacorta, Maria Antonietta
    Blasi, Maria Antonietta
    Tortora, Giampaolo
    Schinzari, Giovanni
    CANCERS, 2023, 15 (02)
  • [7] Ipilimumab in anti-PD1 refractory metastatic melanoma: a report of eight cases
    Jacobsoone-Ulrich, Aurelie
    Jamme, Philippe
    Alkeraye, Salim
    Dzwiniel, Veronique
    Faure, Emmanuel
    Templier, Carole
    Mortier, Laurent
    MELANOMA RESEARCH, 2016, 26 (02) : 153 - 156
  • [8] ANTI-PD1 THERAPY IN PATIENTS WITH METASTATIC MELANOMA: A SINGLE CENTRE EXPERIENCE
    Nguyen, B.
    Robinson, E.
    Arora, A.
    Sayed, A.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 65 - 65
  • [9] Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
    Simeone, Ester
    Ascierto, Paolo A.
    JOURNAL OF IMMUNOTOXICOLOGY, 2012, 9 (03) : 241 - 247
  • [10] TGF-β mRNA levels in circulating extracellular vesicles are associated with response to anti-PD1 treatment in metastatic melanoma
    Crucitta, Stefania
    Cucchiara, Federico
    Marconcini, Riccardo
    Bulleri, Alessandra
    Manacorda, Simona
    Capuano, Annalisa
    Cioni, Dania
    Nuzzo, Amedeo
    de Jonge, Evert
    Mathjissen, Ron H. J.
    Neri, Emanuele
    van Schaik, Ron H. N.
    Fogli, Stefano
    Danesi, Romano
    Del Re, Marzia
    FRONTIERS IN MOLECULAR BIOSCIENCES, 2024, 11
12345